Marinus Pharmaceuticals, Inc
MRNS
MRNS was delisted on the 10th of February, 2025.
0 hedge funds and large institutions have $0 invested in Marinus Pharmaceuticals, Inc in 2025 Q1 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 53 closing their positions.
53.54% less ownership
Funds ownership: 53.54% → 0% (-54%)
100% less funds holding
Funds holding: 53 → 0 (-53)
100% less capital inflows, than outflows
Capital inflows: $0 | Capital outflows: $15.8M
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 53
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Beryl Capital Management
Redondo Beach,
California
|
-$2.26M |
| 2 |
Morgan Stanley
New York
|
-$1.77M |
| 3 |
ODDO BHF Asset Management
Paris,
France
|
-$1.44M |
| 4 |
Bain Capital Life Sciences Investors
Boston,
Massachusetts
|
-$1.44M |
| 5 |
Aberdeen Group
Edinburgh,
United Kingdom
|
-$1.42M |
MRNS Hedge Fund Activity: Q1 2025 in Review
0 of the 7,481 institutional investors tracked by Wall St. Rank reported a position in Marinus Pharmaceuticals, Inc (MRNS) for Q1 2025, worth a combined $0 — down 100% from $15.8M a quarter earlier.
Sellers outnumbered buyers: 53 funds closed out of MRNS and 0 opened new positions — a net loss of 53 holders — while 0 trimmed existing stakes and 0 added.
The largest seller was Beryl Capital Management, exiting entirely with an estimated $2.26M sold.
- 0 institutional investors held Marinus Pharmaceuticals, Inc (MRNS) as of Q1 2025, down from 53 in Q4 2024.
- Funds reported $0 of Marinus Pharmaceuticals, Inc stock for Q1 2025, down 100% quarter-over-quarter.
- 0 funds opened new Marinus Pharmaceuticals, Inc positions in Q1 2025 and 53 closed out, a net change of -53 holders.
- The largest Marinus Pharmaceuticals, Inc seller in Q1 2025 was Beryl Capital Management, an estimated $2.26M sold.
Based on aggregated 13F filings for Q1 2025.